I don't have any hard data to back this up, but I would think the fertility field (omitted from the list) is likely to have one of the highest revenue per sales force size (sales force efficiency) out there..there are very few specialists to target, the expansion of the market has been staggering, and the cost of drugs is enormous
rFSH happens to be going off patent soon, so this should be a ripe target for biosimilars
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.